Inactive Instrument

Novoheart Holdings Inc.

NVH

CA67011V1076

Biotechnology & Medical Research

Novoheart Announces Change of Fiscal Year-End

November 29, 2019 at 09:00 pm EST

Novoheart Holdings Inc. announced that it is changing its fiscal year-end to December 31, from its current fiscal year-end of June 30.

Latest news about Novoheart Holdings Inc.

Novoheart Holdings Inc.(TSXV:NVH) dropped from S&P/TSX Venture Composite Index	20-11-23	CI
Novomed Limited completed the acquisition of 12.6% stake in Novoheart Holdings Inc..	20-11-17	CI
Novomed Limited entered into a definitive arrangement agreement to acquire 12.6% stake in Novoheart Holdings Inc. for CAD 12.6 million.	20-09-14	CI
Novoheart Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-31	CI
Novoheart Holdings Inc. Announces Directorship Appointments	20-05-19	CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-19	CI
Novoheart Holdings Inc. Announces Change of its Fiscal Year-End to December 31, from June 30	20-03-11	CI
Novoheart Announces the Completion of a Research and Development Contract Sponsored by a Top 10 Global Pharma	20-01-21	CI
Novoheart Announces an Exclusive Licensing Agreement with Harvard University's Office of Technology Development	19-12-16	CI
Novoheart Announces Change of Fiscal Year-End	19-11-29	CI
Novoheart Holdings Inc. Announces Management Changes	19-11-29	CI
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca	19-11-26	CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-18	CI
Novoheart Holdings Inc. Demonstrates Advanced Capabilities for Drug Screening as Well as Disease Modeling Which Can Lead to Safer Drugs with Better Efficacy, According to New Research	19-09-09	CI
Novoheart Holdings Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	19-09-05	CI
Novoheart Holdings Inc. completed the acquisition of Xellera Therapeutics Limited from Ruby Fame Limited, Marine Bridge International Limited and Ronald Li.	19-06-27	CI
Novoheart Holdings Inc. Announces Executive Changes	19-06-17	CI
Novoheart Holdings Inc. entered into a definitive agreement to acquire Xellera Therapeutics Limited from Ruby Fame Limited, Marine Bridge International Limited and Ronald Li for CAD 32.6 million.	19-05-27	CI
Novoheart Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2019	19-05-17	CI
Novoheart Holdings Inc.(TSXV:NVH) added to S&P/TSX Venture Composite Index	19-04-22	CI
Novoheart Holdings Inc. Announces Board Appointments	19-03-01	CI
Novoheart Holdings Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2018	19-03-01	CI
Novoheart Holdings Inc. Announces Executive Changes	19-01-07	CI
Novoheart Holdings Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2018	18-11-22	CI
Novoheart Enters into A Service Agreement with Xellera Therapeutics Limited	18-10-31	CI

Novoheart Holdings Inc is a Canada-based holding company. The Company, through its subsidiary, provides, discovers and develops heart therapeutics. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart ânovoHeartâ that is capable of fully capable of pumping and ejecting fluid. It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of this specific disease. Novoheart is currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

Novoheart Holdings Inc.

Equities

NVH

CA67011V1076

Biotechnology & Medical Research

Novoheart Announces Change of Fiscal Year-End

Latest news about Novoheart Holdings Inc.

Chart Novoheart Holdings Inc.

Company Profile

Sector Bio Therapeutic Drugs